Biocause Pharma(SZ:000627) 中国基金报·2025-08-14 06:53Core Viewpoint - The decision of whether *ST Tianmao will voluntarily delist is crucially dependent on the votes of minority shareholders holding less than 5% of the shares, as they will play a key role in the upcoming shareholder meeting [5][8]. Group 1: Shareholder Meeting and Delisting Proposal - *ST Tianmao will hold its first extraordinary general meeting of 2025 on August 25 to discuss the proposal for voluntary delisting [3][10]. - The stock will be suspended from trading starting August 14, 2025, following the registration date for shareholders [3][10]. - The proposal requires approval from two-thirds of the voting rights of all shareholders and two-thirds of the voting rights of minority shareholders [6][10]. Group 2: Current Financial Situation and Risks - The company has not released its 2024 annual report, which poses a risk of being forced to delist [12][13]. - If the company fails to disclose the required annual report within two months after being warned, it will face mandatory delisting [14]. - The stock has been under risk warning since July 8, 2025, due to the failure to disclose financial reports [12][14]. Group 3: Shareholder Dynamics and Cash Option - As of July 18, 2025, *ST Tianmao had approximately 111,900 shareholders, with a significant portion being minority shareholders [9][8]. - A cash option is being offered to all shareholders, including dissenting ones, at a price of 1.60 yuan per share, which provides a potential exit strategy for investors [10][16]. - Following the announcement of the voluntary delisting, the stock price increased nearly 9%, closing at 1.58 yuan per share on August 13, 2025, just below the cash option price [10][16].